You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

List of Excipients in API RIOCIGUAT

✉ Email this page to a colleague

« Back to Dashboard

Excipients in NDA-approved (novel) drugs containing RIOCIGUAT

Subscribe to access the full database, or Get Started Free
Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	ADEMPAS	riociguat	50419-250	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare Pharmaceuticals Inc	ADEMPAS	riociguat	50419-250	CROSPOVIDONE
Bayer HealthCare Pharmaceuticals Inc	ADEMPAS	riociguat	50419-250	HYDROXYPROPYL CELLULOSE
Bayer HealthCare Pharmaceuticals Inc	ADEMPAS	riociguat	50419-250	HYPROMELLOSE
Bayer HealthCare Pharmaceuticals Inc	ADEMPAS	riociguat	50419-250	LACTOSE MONOHYDRATE
>Company	>Tradename	>Ingredient	>NDC	>Excipient	>Potential Generic Entry

Detailed excipient profiles for RIOCIGUAT

Excipient focus: CELLULOSE, MICROCRYSTALLINE

RIOCIGUAT drug variants containing CELLULOSE, MICROCRYSTALLINE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing CELLULOSE, MICROCRYSTALLINE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: CROSPOVIDONE

RIOCIGUAT drug variants containing CROSPOVIDONE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing CROSPOVIDONE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: HYDROXYPROPYL CELLULOSE

RIOCIGUAT drug variants containing HYDROXYPROPYL CELLULOSE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing HYDROXYPROPYL CELLULOSE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: HYPROMELLOSE

RIOCIGUAT drug variants containing HYPROMELLOSE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing HYPROMELLOSE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: LACTOSE MONOHYDRATE

RIOCIGUAT drug variants containing LACTOSE MONOHYDRATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing LACTOSE MONOHYDRATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: MAGNESIUM STEARATE

RIOCIGUAT drug variants containing MAGNESIUM STEARATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing MAGNESIUM STEARATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: PROPYLENE GLYCOL

RIOCIGUAT drug variants containing PROPYLENE GLYCOL

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing PROPYLENE GLYCOL

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: SODIUM LAURYL SULFATE

RIOCIGUAT drug variants containing SODIUM LAURYL SULFATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing SODIUM LAURYL SULFATE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Excipient focus: TITANIUM DIOXIDE

RIOCIGUAT drug variants containing TITANIUM DIOXIDE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
Bayer HealthCare Pharmaceuticals Inc	riociguat	50419-250
>Company	>Ingredient	>NDC

RIOCIGUAT drug variants not containing TITANIUM DIOXIDE

Subscribe to access the full database, or Get Started Free
Company	Ingredient	NDC
>Company	>Ingredient	>NDC

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.